Versant Capital Management Inc Buys 83 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Versant Capital Management Inc boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 77.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 190 shares of the biopharmaceutical company’s stock after purchasing an additional 83 shares during the period. Versant Capital Management Inc’s holdings in Alnylam Pharmaceuticals were worth $45,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 91 shares during the period. Commonwealth Equity Services LLC increased its holdings in Alnylam Pharmaceuticals by 2.8% during the second quarter. Commonwealth Equity Services LLC now owns 5,752 shares of the biopharmaceutical company’s stock valued at $1,398,000 after buying an additional 158 shares during the last quarter. Acadian Asset Management LLC raised its position in Alnylam Pharmaceuticals by 2,148.9% in the second quarter. Acadian Asset Management LLC now owns 37,310 shares of the biopharmaceutical company’s stock worth $9,062,000 after acquiring an additional 35,651 shares during the period. Ballentine Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $338,000. Finally, HCR Wealth Advisors bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $225,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.5 %

NASDAQ ALNY opened at $233.15 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a market capitalization of $30.07 billion, a price-to-earnings ratio of -88.99 and a beta of 0.34. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The company has a fifty day moving average of $251.91 and a two-hundred day moving average of $259.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on ALNY shares. Chardan Capital restated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. TD Cowen lifted their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.